At its Annual General Meeting on June 10, 2026, uniQure N.V. shareholders approved several material corporate changes. These include an increase in the company's authorized share capital and an amendment to the Amended and Restated 2014 Share Incentive Plan to increase the number of ordinary shares reserved for issuance. Shareholders also approved amendments to the Articles of Association to reflect the Dutch large company regime and establish U.S. federal district courts as the exclusive forum for certain legal disputes. Additionally, the company reappointed Madhavan Balachandran, Jack Kaye, and Leonard Post as non-executive directors through 2029. uniQure N.V. is a biotechnology company that develops gene therapies for neurological and liver diseases.
